Inflammatory bowel syndrome (IBS) is the most common gastrointestinal disorder seen by primary care providers, yet it remains a source of frustration for both patients and physicians. Recent advances in our understanding of the etiology and pathophysiology of IBS have led to new diagnostic guidelines that avoid unnecessary testing so that IBS is no longer a diagnosis of exclusion. Treatment options are varied and evolving and include pharmacologic and non-pharmacologic options depending on the subtype of IBS and individual patient characteristics. This archived symposium will provide participants with the opportunity to assess new data and remaining challenges in the diagnosis and treatment of patients with IBS via interactive case scenarios.
Find the latest free continuing medical education courses in gastroenterology to help you receive the CME credits you need.
This webcast on gastric cancer (GC) is based on a roundtable discussion among three key opinion leaders in the field. The experts will present updates on the management of GC and summarize and discuss the latest clinical trial data presented during the ESMO 2017 Congress, held in Madrid, Spain, and the 2017 ASCO Annual Meeting, held in Chicago, USA. Advances in perioperative treatment strategies, targeted therapies such as HER2 inhibitors, and novel immunotherapies including agents targeting PD-1/PD-L1 will be examined. The experts will address the question of how novel treatment options, when approved, could be included in individualized treatment plans, to optimize treatment selection and outcomes for patients with GC.
ESMO 2017: A Therapeutic Update on the Management of Patients with Advanced Hepatocellular CarcinomaFormat: Medical Meeting Reporter
This webcast on hepatocellular carcinoma (HCC) is based on a presentation by an expert, who provides an overview of the advances in the management of HCC and summarizes and discusses the latest data presented during the European Society for Medical Oncology (ESMO) Annual Meeting 2017, held on September 8-12 in Madrid, Spain. Results of clinical trials of targeted therapies that have been evaluated in first-line and second-line setting in advanced HCC and their possible effect on treatment guidelines will be examined. Additionally, the potential role of biomarkers as prognostic factors of response to targeted therapies, particularly in clinical practice, will also be discussed. The expert will also discuss the most promising new agents in advanced clinical trials in HCC and how they might impact the treatment landscape in HCC.